Protalix BioTherapeutics, Inc. (FRA:PBDA)

Market Cap	158.40M +2.0%
Revenue (ttm)	52.71M +35.4%
Net Income	4.60M
EPS	0.06
Shares Out	n/a
PE Ratio	34.45
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	140
Open	1.700
Previous Close	1.720
Day's Range	1.700 - 1.960
52-Week Range	1.140 - 2.700
Beta	n/a
RSI	72.51
Earnings Date	Mar 17, 2026

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell e...

• Industry: Biological Products, Except Diagnostic Substances
• CEO: Dror Bashan
• Employees: 213
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PBDA

Financial Performance

In 2024, Protalix BioTherapeutics's revenue was $53.40 million, a decrease of -18.47% compared to the previous year's $65.49 million. Earnings were $2.93 million, a decrease of -64.73%.

Financial numbers in USD